津药药业 (600488.SH) Latest Company News

Aug 25, 2026, 10:58 UTC
Jinyao Pharmaceutical announced its 2026 first-half results: net profit attributable to shareholders was 43.1735 million yuan, down 12.43% year-on-year.
Source:
- finance.sina.cn
Aug 17, 2026, 07:34 UTC
Tianjin Pharmaceutical's subsidiary Jin Yao Heping (Tianjin) Pharmaceutical Co., Ltd. received a drug registration certificate from the Myanmar Ministry of Health for its pediatric compound amino acid injection (18AA-I), allowing production and sale in Myanmar.
Source:
- finance.sina.cn
Aug 14, 2026, 07:33 UTC
Tianjin Jinyao Pharmaceutical's subsidiary Hubei Jinyao received regulatory approval to add a new specification (1ml:0.1g) of vitamin B6 injection and passed generic drug consistency evaluation.
Source:
- finance.sina.cn
Aug 7, 2026, 07:33 UTC
Tianjin Pharmaceutical's subsidiary Hubei Tianjin Pharmaceutical received a drug registration certificate from the National Medical Products Administration for tranexamic acid sodium chloride injection, used to treat various bleeding caused by primary hyperfibrinolysis, and the approval is deemed to have passed the generic drug quality and efficacy consistency evaluation.
Source:
- finance.sina.cn
Aug 4, 2026, 08:02 UTC
Jinyao Pharmaceutical's controlled subsidiary Jinyao Heping's compound potassium dihydrogen phosphate injection is proposed to be selected in the 12th national drug centralized procurement, with a proposed winning price of 0.89 yuan per vial, and the procurement period until December 31, 2029.
Source:
- finance.sina.cn
Aug 3, 2026, 07:32 UTC
Jinyao Pharmaceutical's subsidiary Hubei Jinyao received a drug registration certificate from the National Medical Products Administration for Compound Electrolyte Injection, specification 500ml, approval number Guoyao Zhunzi H20265388, registration category Chemical Drug Class 4.
Source:
- finance.sina.cn
Jul 7, 2026, 12:47 UTC
Tianjin Tianyao Pharmaceuticals received approval from the Brazilian Health Regulatory Agency for its betamethasone active pharmaceutical ingredient to be marketed in Brazil.
Source:
- finance.sina.cn

600488.SH

Jinyao Pharmaceutical announced its 2026 first-half results: net profit attributable to shareholders was 43.1735 million yuan, down 12.43% year-on-year.

Tianjin Pharmaceutical's subsidiary Jin Yao Heping (Tianjin) Pharmaceutical Co., Ltd. received a drug registration certificate from the Myanmar Ministry of Health for its pediatric compound amino acid injection (18AA-I), allowing production and sale in Myanmar.

Tianjin Jinyao Pharmaceutical's subsidiary Hubei Jinyao received regulatory approval to add a new specification (1ml:0.1g) of vitamin B6 injection and passed generic drug consistency evaluation.

Jinyao Pharmaceutical's controlled subsidiary Jinyao Heping's compound potassium dihydrogen phosphate injection is proposed to be selected in the 12th national drug centralized procurement, with a proposed winning price of 0.89 yuan per vial, and the procurement period until December 31, 2029.

Jinyao Pharmaceutical's subsidiary Hubei Jinyao received a drug registration certificate from the National Medical Products Administration for Compound Electrolyte Injection, specification 500ml, approval number Guoyao Zhunzi H20265388, registration category Chemical Drug Class 4.

Tianjin Tianyao Pharmaceuticals received approval from the Brazilian Health Regulatory Agency for its betamethasone active pharmaceutical ingredient to be marketed in Brazil.